Handelsbanken Fonder AB Has $125.51 Million Stake in Amgen Inc. $AMGN

Key Points

• Handelsbanken Fonder increased its Amgen stake by 15.7% in the second quarter, adding 47,052 shares to own 346,596 shares valued at approximately $125.5 million. Institutional investors collectively hold 76.5% of Amgen’s stock.
• Amgen reported quarterly earnings of $6.29 per share on $10.05 billion in revenue, beating analyst expectations, while revenue rose 9.5% year over year. The company issued full-year 2026 EPS guidance of $22.30–$23.50.
• Amgen declared a quarterly dividend of $2.52 per share, equivalent to $10.08 annually and a 2.4% yield. Analysts remain mixed, with a consensus “Hold” rating and an average price target of $371.68.

Handelsbanken Fonder AB lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 15.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 346,596 shares of the medical research company's stock after buying an additional 47,052 shares during the quarter. Handelsbanken Fonder AB owned about 0.06% of Amgen worth $125,509,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. raised its holdings in shares of Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock valued at $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC raised its holdings in shares of Amgen by 11.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company's stock valued at $1,141,000 after purchasing an additional 416 shares in the last quarter. Finally, Ieq Capital LLC lifted its stake in shares of Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company's stock valued at $15,120,000 after purchasing an additional 2,611 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Trading Up 1.5%

Shares of AMGN stock opened at $417.20 on Tuesday. The firm has a market capitalization of $225.55 billion, a P/E ratio of 25.93, a price-to-earnings-growth ratio of 3.82 and a beta of 0.41. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $418.40. The firm's fifty day simple moving average is $364.54 and its 200 day simple moving average is $357.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business's revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.85% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMGN. TD Cowen upped their price objective on shares of Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Citigroup raised their target price on Amgen from $345.00 to $405.00 and gave the company a "neutral" rating in a report on Friday. Piper Sandler reaffirmed an "overweight" rating on shares of Amgen in a research report on Friday, June 12th. Wells Fargo & Company upped their price target on Amgen from $390.00 to $400.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 5th. Finally, Robert W. Baird increased their price objective on Amgen from $215.00 to $230.00 and gave the company an "underperform" rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $371.68.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source